Risk of Recurrent Staphylococcus aureus Prosthetic Joint Infection in Rheumatoid Arthritis Patients-A Nationwide Cohort Study

Namrata Singh, Rajeshwari Nair, Michihiko Goto, Martha L Carvour, Ryan Carnahan, Elizabeth H Field, Petar Lenert, Mary Vaughan-Sarrazin, Marin L Schweizer, Eli N Perencevich, Namrata Singh, Rajeshwari Nair, Michihiko Goto, Martha L Carvour, Ryan Carnahan, Elizabeth H Field, Petar Lenert, Mary Vaughan-Sarrazin, Marin L Schweizer, Eli N Perencevich

Abstract

Background: Treatment of rheumatoid arthritis (RA) often involves immune-suppressive therapies. Concern for recurrent prosthetic joint infection (PJI) in RA patients might be high and could reduce use of joint implantation in these patients. We aimed to evaluate the risk of recurrence of PJI in RA patients compared with osteoarthritis (OA) patients by utilizing a large health care system.

Methods: We conducted a retrospective cohort study of all patients admitted for a Staphylococcus aureus PJI who underwent debridement, antibiotics, and implant retention (DAIR) or 2-stage exchange (2SE) between 2003 and 2010 at 86 Veterans Affairs Medical Centers. Both RA patients and the comparison group of osteoarthritis (OA) patients were identified using International Classification of Diseases, Ninth Revision, codes. All index PJI and recurrent positive cultures for S. aureus during 2 years of follow-up were validated by manual chart review. A Cox proportional hazards regression model was used to compare the time to recurrent PJI for RA vs OA.

Results: In our final cohort of 374 veterans who had either DAIR or 2SE surgery for their index S. aureus PJI, 11.2% had RA (n = 42). The majority of the cohort was male (97.3%), and 223 (59.6%) had a methicillin-susceptible S. aureus PJI. RA patients had a similar risk of failure compared with OA patients, after adjusting for covariates (hazard ratio, 0.81; 95% confidence interval, 0.48-1.37).

Conclusions: Prior diagnosis of RA does not increase the risk of recurrent S. aureus PJI. Further studies are needed to evaluate the effect of different RA therapies on outcomes of episodes of PJI.

Keywords: Staphylococcus aureus; recurrent prosthetic joint infection; rheumatoid arthritis.

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Failure curve for time to treatment failure in Staphylococcus aureus prosthetic joint infection patients.
Figure 2.
Figure 2.
Failure curve for time to microbiological recurrence with or without revision surgery in Staphylococcus aureus prosthetic joint infection patients.

References

    1. Kurtz S, Ong K, Lau E, et al. . Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007; 89:780–5.
    1. Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev 2014; 27:302–45.
    1. Berbari EF, Hanssen AD, Duffy MC, et al. . Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998; 27:1247–54.
    1. Morrison TA, Figgie M, Miller AO, Goodman SM. Periprosthetic joint infection in patients with inflammatory joint disease: a review of risk factors and current approaches to diagnosis and management. HSS J 2013; 9:183–94.
    1. Doran MF, Crowson CS, Pond GR, et al. . Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:2287–93.
    1. Schrama JC, Espehaug B, Hallan G, et al. . Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res (Hoboken) 2010; 62:473–9.
    1. Bongartz T, Halligan CS, Osmon DR, et al. . Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59:1713–20.
    1. Poss R, Thornhill TS, Ewald FC, et al. . Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 1984; 117–26.
    1. Jämsen E, Varonen M, Huhtala H, et al. . Incidence of prosthetic joint infections after primary knee arthroplasty. J Arthroplasty 2010; 25:87–92.
    1. Jamsen E, Huhtala H, Puolakka T, Moilanen T. Risk factors for infection after knee arthroplasty. A register-based analysis of 43,149 cases. J Bone Joint Surg Am 2009; 91:38–47.
    1. Ravi B, Escott B, Shah PS, et al. . A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. Arthritis Rheum 2012; 64:3839–49.
    1. Cordtz RL, Zobbe K, Hojgaard P, et al. . Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers. Ann Rheum Dis 2018; 77:281–8.
    1. Hsieh PH, Huang KC, Shih HN. Prosthetic joint infection in patients with rheumatoid arthritis: an outcome analysis compared with controls. PLoS One 2013; 8:e71666.
    1. Albertson J, McDanel JS, Carnahan R, et al. . Determination of risk factors for recurrent methicillin-resistant Staphylococcus aureus bacteremia in a Veterans Affairs healthcare system population. Infect Control Hosp Epidemiol 2015; 36:543–9.
    1. Knaus WA, Wagner DP, Draper EA, et al. . The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619–36.
    1. Senneville E, Joulie D, Legout L, et al. . Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011; 53:334–40.
    1. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351:1645–54.
    1. Lora-Tamayo J, Senneville É, Ribera A, et al. ; Group of Investigators for Streptococcal Prosthetic Joint Infection The not-so-good prognosis of streptococcal periprosthetic joint infection managed by implant retention: the results of a large multicenter study. Clin Infect Dis 2017; 64:1742–52.
    1. Hsieh PH, Lee MS, Hsu KY, et al. . Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis 2009; 49:1036–43.
    1. Azzam KA, Seeley M, Ghanem E, et al. . Irrigation and debridement in the management of prosthetic joint infection: traditional indications revisited. J Arthroplasty 2010; 25:1022–7.
    1. Kuiper JW, Vos SJ, Saouti R, et al. . Prosthetic joint-associated infections treated with DAIR (debridement, antibiotics, irrigation, and retention): analysis of risk factors and local antibiotic carriers in 91 patients. Acta Orthop 2013; 84:380–6.
    1. Goodman SM, Figgie MA. Arthroplasty in patients with established rheumatoid arthritis (RA): mitigating risks and optimizing outcomes. Best Pract Res Clin Rheumatol 2015; 29:628–42.
    1. Goodman SM, Menon I, Christos PJ, et al. . Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology (Oxford) 2016; 55:573–82.
    1. McConoughey SJ, Howlin R, Granger JF, et al. . Biofilms in periprosthetic orthopedic infections. Future Microbiol 2014; 9:987–1007.
    1. Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol Med Microbiol 2012; 65:158–68.
    1. Berbari EF, Osmon DR, Duffy MC, et al. . Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes. Clin Infect Dis 2006; 42:216–23.
    1. Jain R, Kralovic SM, Evans ME, et al. . Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011; 364:1419–30.
    1. Singh JA, Holmgren AR, Noorbaloochi S. Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 2004; 51:952–7.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren